Type 2 diabetes and cancer: should we prefer antihyperglycaemic treatments without unnecessarily increasing insulin levels?

Diab Vasc Dis Res. 2014 Nov;11(6):370. doi: 10.1177/1479164114550641. Epub 2014 Sep 23.

Author

Stephan Matthaei¹

Affiliation

¹ Diabetology, Endocrinology and Metabolism, Diabetes-Center, Quakenbrück, Germany S.Matthaei@ckq-gmbh.de.

PMID: 25249176
DOI: 10.1177/1479164114550641

No abstract available

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Humans
Hyperinsulinism / chemically induced*
Hyperinsulinism / complications
Hypoglycemic Agents / adverse effects*
Insulin / adverse effects*
Neoplasms / etiology*

Substances

Hypoglycemic Agents
Insulin